The 2019 FASEB abstract by Dokuzovic et al. demonstrates that bilateral stripping of paravertebral muscles from the L3–L4 lumbar segment in rats produces measurable spinal instability that BPC-157, delivered in drinking water, substantially counteracts. The effect is attributed to the peptide's capacity to restore connective-tissue integrity, promote angiogenesis, and attenuate the secondary inflammatory cascade driving progressive instability after paraspinal disruption.
How Was the Spinal Instability Rat Model Designed in the Dokuzovic Study?
The Dokuzovic et al. (FASEB J, 2019) model created spinal instability by surgically peeling bilateral paravertebral muscles from the L3–L4 lumbar segment, exposing the posterior bony elements. This preparation isolates the contribution of paraspinal musculature to segmental stability without directly transecting the spinal cord, making it distinct from the compression-injury models used in earlier BPC-157 spinal cord work.
The model builds on a prior L2–L3 compression paradigm from the same research group, which had already established BPC-157's capacity to improve spinal cord injury outcomes in rats. The muscle-stripping design shifts the injury locus from neural tissue to the musculoligamentous support structures, more closely approximating the biomechanical failure pattern seen in degenerative lumbar instability in humans.
Spinal instability in this context refers to pathological motion at the L3–L4 segment resulting from loss of the dynamic muscular stabilisers. Without intact paraspinal musculature, the segment relies entirely on passive ligamentous and bony constraints, which are insufficient to prevent abnormal intervertebral movement under physiological loading. The model therefore generates a chronic, biomechanically relevant instability rather than an acute traumatic lesion.
BPC-157 was administered in the drinking water, a route validated across multiple prior BPC-157 musculoskeletal and neurological studies as producing systemic bioavailability sufficient to generate tissue-level effects. This oral delivery route is mechanistically notable because it implies the peptide survives gastrointestinal transit at concentrations adequate to reach paraspinal tissues.
What Specific Outcomes Did BPC-157 Counteract in the Instability Model?
The FASEB abstract reports that BPC-157 treatment improved damage caused by spine instability in the muscle-stripping model, with the authors concluding the peptide has potential utility for chronic back pain. The abstract does not specify individual histological or biomechanical endpoints in granular detail, consistent with its conference-abstract format, but the finding is contextualised by the broader BPC-157 spinal literature.
The 2019 full-length paper by Perovic et al. in the Journal of Orthopaedic Surgery and Research (PMC6604284) — addressing the related L2–L3 compression model — documented that BPC-157-treated rats showed recovery across the acute, subacute, subchronic, and chronic phases of secondary injury. This multi-phase recovery profile is relevant to the instability model because paraspinal muscle disruption also triggers a secondary inflammatory and fibrotic cascade that evolves over weeks.
The 2022 MDPI review by Perovic et al. (PMC9164058) extended these findings, reporting that BPC-157 counteracts axonal and neuronal necrosis, demyelination, and cyst formation in spinal cord injury preparations. While the instability model does not produce direct cord compression, the secondary inflammatory milieu generated by paraspinal disruption can impinge on neural structures over time, making these neuroprotective endpoints mechanistically relevant.
Functional recovery in BPC-157-treated spinal injury rats has been assessed using tail function scoring, hindlimb motor grading, and Luxol fast blue staining for myelin integrity. The 2022 Perovic study reported that BPC-157 rats showed rapid tail function recovery and absence of demyelination on Luxol fast blue staining, contrasting with vehicle-treated controls that showed persistent deficits.
Which Molecular Pathways Mediate BPC-157's Effect on Paraspinal Connective Tissue?
BPC-157's connective-tissue effects in the paraspinal context operate through three intersecting pathways: focal adhesion kinase (FAK)–paxillin signalling driving fibroblast proliferation and collagen synthesis; VEGF-dependent angiogenesis restoring vascular supply to disrupted muscle; and growth hormone receptor upregulation in tendon fibroblasts amplifying the local anabolic response. These pathways are documented across BPC-157 musculoskeletal studies and are mechanistically applicable to paraspinal tissue.
The FAK–paxillin axis is the best-characterised BPC-157 tendon mechanism. Chang et al. (J Appl Physiol, 2011) demonstrated that BPC-157 promotes ex vivo outgrowth of tendon fibroblasts from explants, enhances cell survival under oxidative stress, and accelerates in vitro fibroblast migration — all via FAK activation. Paraspinal muscles contain dense connective tissue sheaths and musculotendinous junctions that would be subject to the same FAK-dependent repair signalling.
VEGF upregulation by BPC-157 is documented in multiple tissue contexts and is mechanistically critical for paraspinal recovery. Surgical muscle stripping disrupts the segmental blood supply to the posterior spinal elements; without adequate revascularisation, the repair process stalls in a hypoxic, pro-fibrotic state. BPC-157-driven angiogenesis would restore oxygen and nutrient delivery, enabling fibroblast-mediated matrix remodelling to proceed.
Growth hormone receptor upregulation in tendon fibroblasts, documented by Krivic et al. at both mRNA and protein levels, provides an additional anabolic amplification mechanism. Paraspinal muscles and their fascial attachments express growth hormone receptors; enhanced receptor density would sensitise these tissues to circulating GH, potentially accelerating the hypertrophic response needed to restore dynamic segmental stabilisation.
What Is the Broader Preclinical Evidence Base for BPC-157 in Spinal Pathology?
The spinal evidence base for BPC-157 spans at least four distinct rat model preparations: L2–L3 cord compression (Perovic 2019), the L3–L4 paravertebral muscle-stripping instability model (Dokuzovic 2019), a definitive spinal cord injury model with tail paralysis (Perovic 2022), and a CNS review synthesis (PMC8504390, 2021). All four preparations report directionally consistent benefit across different injury mechanisms and outcome domains.
The 2021 CNS review (PMC8504390) by Sikiric et al. synthesised the spinal cord evidence alongside BPC-157's broader central nervous system effects, noting that the peptide's anti-inflammatory, pro-angiogenic, and neuroprotective properties converge on the spinal cord as a target organ. The review specifically highlighted the tail paralysis compression model as demonstrating that BPC-157 therapy "can impact all stages of the secondary injury phase" — a mechanistic claim with direct relevance to the instability model's chronic inflammatory component.
A 2026 MDPI review by Yuan et al. (IJMS, doi:10.3390/ijms27062876) on BPC-157 in tissue repair and pain management confirmed that the peptide supports angiogenesis, collagen synthesis, fibroblast activity, and nitric oxide pathway modulation across musculoskeletal injury contexts. This 2026 synthesis represents the most current independent corroboration of the mechanistic framework underlying the spinal instability findings.
What Are the Key Limitations of the Spinal Instability Evidence?
The primary limitation is that the Dokuzovic spinal instability data exist only as a conference abstract in the FASEB Journal supplement series, not as a peer-reviewed full-length article. Conference abstracts are not subject to the same methodological scrutiny as primary research papers, and granular data on sample sizes, blinding procedures, and quantitative outcome measures are unavailable in abstract format.
The broader BPC-157 spinal literature is dominated by a single research group at the University of Zagreb, led by Predrag Sikiric. This concentration of output from one laboratory introduces replication risk: independent groups have not systematically reproduced the paraspinal instability findings, and the absence of independent replication is a recognised limitation in the BPC-157 field more broadly. A 2025 PMC narrative review (PMC12446177) acknowledged this constraint while noting the mechanistic consistency across the Zagreb group's output.
All evidence is preclinical. The rat paravertebral muscle-stripping model approximates human degenerative lumbar instability in biomechanical terms but differs in scale, healing kinetics, and the immunological environment. Rodent paraspinal muscles heal faster than human equivalents, and the pharmacokinetics of orally administered BPC-157 in rats may not translate directly to human dosing requirements. No human clinical trial has evaluated BPC-157 in any form of spinal instability.
The FASEB abstract reports BPC-157 given in drinking water without specifying the concentration used. Drinking-water delivery produces variable intake depending on individual animal hydration behaviour, introducing dose uncertainty. The Perovic 2019 full paper used both intraperitoneal injection and drinking-water routes, finding efficacy with both, but the instability abstract's reliance on drinking water alone limits pharmacokinetic precision.
How Does the Spinal Instability Finding Fit the 2026 BPC-157 Translational Landscape?
In 2026, BPC-157 remains entirely preclinical for spinal indications. A Phase 2 RCT in hamstring strain (NCT07437547) is registered but unpublished, representing the closest registered human trial in a related musculoskeletal context. The spinal instability data contribute to the mechanistic rationale for future spinal trials but do not constitute clinical evidence of any kind.
The 2026 Pharmaceutics review on BPC-157 formulation barriers (doi:10.3390/pharmaceutics18050625) identified four translational obstacles: a sub-16-minute IV half-life, species-variable bioavailability, absent GLP toxicology data, and no GMP manufacturing pathway. These barriers apply equally to any potential spinal instability indication and would need to be resolved before a human spinal trial could be designed. Nanoparticle encapsulation and lipid-based carriers are under evaluation as formulation strategies that could extend the effective half-life.
The drinking-water delivery route used in the Dokuzovic model is mechanistically interesting from a translational standpoint because it suggests oral bioavailability sufficient for paraspinal tissue effects. If confirmed in pharmacokinetic studies, oral delivery would substantially lower the barrier to human trial design compared with injectable formulations, which face greater regulatory and manufacturing complexity. What Does 2026 Research Reveal About BPC-157 in Tissue Repair and Pain Management? What Does 2026 Research Reveal About BPC-157 for Musculoskeletal Healing — Regeneration or Risk? Does BPC-157 Outperform TB-500 for Tendon and Ligament Healing via Angiogenesis in 2026?